GLP-1 vs GLP-2 vs GLP-3 Explained: The Naming Confusion, the Real Science, and What You're Actually Buying

If you have been told to "go buy a GLP-2" or searched a research supplier site for retatrutide and found something called GLP3-RT instead, you are not alone. The naming situation in the GLP compound space has become genuinely confusing - a mix of real endocrinology, informal community shorthand, and supplier relabeling conventions that do not map cleanly onto the actual pharmacology.

This article exists to sort all of that out. What these informal names actually point to. What the real science says about how these compounds work. And how to decode whatever label you are looking at on any given supplier site.

What "GLP" Actually Stands For - and Why the Numbers Are Misleading

GLP stands for Glucagon-Like Peptide. That much is real endocrinology. The body produces several peptide hormones derived from the same precursor protein - proglucagon - and researchers numbered them sequentially based on discovery order.

Here is where the confusion starts. In formal science and medicine, there are real hormones called GLP-1 and GLP-2. They exist. They have documented functions. They are both derived from proglucagon. But they do completely different things in the body, and neither of them is "GLP-3" - because GLP-3 does not exist as a formally recognized hormone or drug class in mainstream pharmacology or endocrinology.

So when the research peptide community uses the terms GLP-1, GLP-2, and GLP-3 to refer to semaglutide, tirzepatide, and retatrutide, they are borrowing a real naming convention and repurposing it as shorthand. The shorthand is not scientifically accurate - but it has stuck, and it is now widely used on supplier sites, in online communities, and in informal discussions about these compounds.

Understanding the gap between the community shorthand and the actual science is exactly what this article covers.

The Research Community Naming Convention - A Decoder Guide

Before going any deeper into the science, here is the practical decoder. If you are looking at a supplier site or reading a community discussion and you see any of these names, here is what they actually refer to.

GLP-1 Labels - These All Mean Semaglutide

In the research peptide community, "GLP-1" as a product category has become informal shorthand for semaglutide - the GLP-1 receptor agonist most people know through brand names like Ozempic and Wegovy. Supplier relabeling variations you may encounter include:

• GLP-1 (base label)
• GLP1-S
• GLP1-SG
• GLP1-SEMA

All of these refer to the same compound: semaglutide. The suffix variations exist because different suppliers use different shorthand conventions, and some add a letter to distinguish their labeling from others. The underlying compound is identical.

GLP-2 Labels - These All Mean Tirzepatide

"GLP-2" in this informal system refers to tirzepatide - the dual GIP/GLP-1 receptor agonist sold under the brand names Mounjaro and Zepbound. Supplier relabeling variations include:

• GLP-2 (base label)
• GLP2-T
• GLP2-TIRZ
• GLP2-TZ

Again, all the same compound. The "2" in this community shorthand does not refer to the actual GLP-2 hormone (which is a real gut-repair hormone with nothing to do with weight loss or glucose regulation). It is simply the second compound in the community's informal numbering of these drugs.

GLP-3 Labels - These All Mean Retatrutide

"GLP-3" in community shorthand refers to retatrutide - the triple agonist (GLP-1 plus GIP plus glucagon receptor) that is currently in Phase 3 clinical trials. Supplier relabeling variations include:

• GLP-3 (base label)
• GLP3-R
• GLP3-RT
• GLP3-RET

Retatrutide is the most advanced compound in this class still under clinical development. It is not FDA-approved for any indication as of this writing. When suppliers label it with GLP-3 variants, they are using the community shorthand - but the compound is retatrutide, not some drug called "GLP-3."

Why Suppliers Relabel Compounds This Way

The relabeling practice exists for a few converging reasons. First, name recognition and search behavior. "GLP-1" is a term people now search because of how heavily it has been covered in mainstream media coverage of Ozempic and Wegovy. Suppliers that use GLP-adjacent naming get pickup in those searches.

Second, regulatory distance. Using an informal label rather than the actual pharmaceutical name - semaglutide, tirzepatide, retatrutide - creates some separation from the regulated drug names. Research compound suppliers operate in a specific legal space, and using the informal community label instead of the INN (International Nonproprietary Name) reflects that.

Third, community convention has a momentum of its own. Once a community starts calling something "GLP-2," the label spreads and suppliers who do not use it become harder to find by buyers who are searching with the community term. The relabeling becomes self-reinforcing.

None of this changes what the compounds are or how they work. The label GLP3-RT on a supplier site means the vial contains retatrutide. The pharmacology of retatrutide does not change because someone put a different name on the label.

The Real Science - What the GLP-1 Receptor System Actually Is

Now that the decoder is established, it is worth understanding what the actual GLP-1 receptor system is and why semaglutide, tirzepatide, and retatrutide all connect to it - even though the community has labeled them as three distinct "GLPs."

GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring incretin hormone your body produces. Incretin hormones are released by the gut in response to food intake and play a key role in regulating blood sugar. GLP-1 is secreted by L-cells in the small intestine, and its natural job includes several important functions:

• Stimulating insulin secretion from the pancreas in a glucose-dependent way - meaning it only triggers insulin release when blood sugar is actually elevated, which is why GLP-1 receptor agonists do not cause hypoglycemia on their own
• Suppressing glucagon, the hormone that tells the liver to release stored glucose
• Slowing gastric emptying, which extends the feeling of fullness after eating
• Signaling to the hypothalamus to reduce hunger and food cravings

The problem with natural GLP-1 is that it has a very short half-life. The enzyme DPP-4 (dipeptidyl peptidase-4) degrades it within minutes of secretion. That is why pharmaceutical GLP-1 receptor agonists were developed - synthetic molecules that mimic GLP-1's effects but resist DPP-4 degradation, allowing them to stay active for hours or days rather than minutes.

Semaglutide, the compound the research community calls "GLP-1," has 94% structural homology to human GLP-1. It works by activating the same receptor - the GLP-1 receptor - that natural GLP-1 activates, but it resists DPP-4 degradation and has a half-life of approximately one week, which is why it is dosed weekly. Studies through the STEP clinical trial program found average weight loss of approximately 15% of body weight over 68 weeks at the standard 2.4 mg weekly dose, with the STEP UP trial showing 20.7% average weight reduction at 7.2 mg weekly.

The Incretin System - GLP-1, GIP, and Glucagon in Plain Language

To understand why tirzepatide is called a "dual agonist" and retatrutide a "triple agonist," you need a working understanding of the three receptor systems involved. This is the actual science behind the community's numbering convention.

GLP-1 Receptor - The Foundation

The GLP-1 receptor is the shared foundation for all three compounds. It sits on pancreatic beta-cells, gut cells, and neurons in the brain's hypothalamus. When activated, it drives the effects described above - glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, and appetite reduction.

Every compound in this discussion - semaglutide, tirzepatide, retatrutide - activates the GLP-1 receptor. That is why calling them all "GLP" anything is not entirely wrong. They all engage this system. The differences lie in what else they activate on top of it.

GIP Receptor - The Second System

GIP stands for Glucose-Dependent Insulinotropic Polypeptide. It is another incretin hormone, distinct from GLP-1, also secreted by the gut after eating. GIP has its own receptor - the GIP receptor - and it also plays a role in insulin secretion and metabolic regulation.

For a long time, researchers considered GIP receptor activation less important than GLP-1 receptor activation for clinical applications. Tirzepatide changed that picture considerably. Tirzepatide activates both the GIP receptor and the GLP-1 receptor - which is why it is called a dual agonist and why the community informally labeled it "GLP-2." One important nuance from the research: in human pancreatic tissue, insulin secretion appears to be driven primarily by the GIP receptor (rather than the GLP-1 receptor), which may help explain tirzepatide's stronger metabolic performance relative to GLP-1-only compounds.

Tirzepatide also exhibits what researchers call "biased agonism" at the GLP-1 receptor - it preferentially signals through the cAMP pathway rather than triggering beta-arrestin recruitment. This signaling bias may increase receptor surface expression and extend the metabolic effect.

Glucagon Receptor - The Third System

Glucagon is a hormone produced by the pancreas that does the opposite of insulin - it tells the liver to release stored glucose, raising blood sugar. In the context of obesity and metabolic health, glucagon receptor activation also increases energy expenditure and promotes fat breakdown.

Retatrutide - the compound the community labels "GLP-3" - activates all three receptors: GLP-1, GIP, and glucagon. This is what makes it a triple agonist. Adding glucagon receptor activity on top of dual GIP/GLP-1 activation is theorized to amplify energy expenditure effects beyond what dual agonism alone produces, which is why Phase 2 trial results for retatrutide showed weight loss figures that exceeded both semaglutide and tirzepatide in head-to-head context.

What "GLP-2" and "GLP-3" Actually Mean in Real Endocrinology

Here is where the community shorthand creates genuine confusion, because GLP-2 is a real thing in formal science - just not the thing the research peptide community means by it.

The Real GLP-2 Hormone

GLP-2 (Glucagon-Like Peptide-2) is a genuine endogenous hormone, derived from the same proglucagon precursor gene as GLP-1. But its function is completely different. GLP-2's primary role is intestinal trophic support - it promotes growth and repair of the intestinal lining, reduces gut permeability (the mechanism underlying what some call "leaky gut"), increases nutrient absorption in the small intestine, and reduces intestinal inflammation.

GLP-2 does not stimulate insulin secretion in any clinically meaningful way. It does not suppress appetite. It is not a weight loss hormone. The only FDA-approved drug based on the GLP-2 hormone is teduglutide (brand name Gattex), and it is approved exclusively for Short Bowel Syndrome - a condition where patients cannot absorb nutrients properly due to loss of intestinal length. GLP-2 analogs have nothing to do with diabetes treatment or body weight management.

When the research peptide community says "GLP-2" and means tirzepatide, they are using a label that formally refers to something completely unrelated. Tirzepatide has no GLP-2 activity. It activates the GIP receptor and the GLP-1 receptor. The "2" in the community label means "the second drug in our informal lineup," not "this compound acts on the GLP-2 receptor."

The Non-Existence of "GLP-3" in Formal Science

There is no established, formally recognized hormone called GLP-3 in mainstream endocrinology or pharmacology. The proglucagon gene does produce additional peptide fragments beyond GLP-1 and GLP-2, but none are characterized and clinically deployed under the name "GLP-3" in any recognized drug development or endocrine research framework.

When suppliers label retatrutide as "GLP-3," they are using the community's informal numbering convention - the third drug in the sequence gets the number 3. Retatrutide does not act on a GLP-3 receptor because there is no GLP-3 receptor. It acts on the GLP-1 receptor, the GIP receptor, and the glucagon receptor, which is why its correct pharmacological classification is "triple GLP-1/GIP/glucagon receptor agonist."

This distinction matters because consumers encountering "GLP-3" products that are not retatrutide - supplements marketed as "GLP-3 activators," for instance - have no pharmacological basis to evaluate. "GLP-3" supplements are not activating a GLP-3 receptor because no such receptor exists in the way these products imply.

How the Drug Class Has Evolved - From Single to Dual to Triple Agonists

The community's 1-2-3 numbering actually does capture one real thing: the progression of the drug class from simpler to more mechanistically complex compounds. Understanding that progression makes the numbering convention less arbitrary.

Generation One - Pure GLP-1 Receptor Agonists

The first generation of GLP-1 receptor agonist drugs include liraglutide (Victoza, Saxenda) and semaglutide (Ozempic, Wegovy, Rybelsus). These compounds activate only the GLP-1 receptor. Semaglutide is the most potent of these and the most widely used in both clinical settings and the research peptide community.

The clinical evidence base for semaglutide is substantial. The STEP clinical trial program established the 2.4 mg weekly subcutaneous dose as the standard for obesity management, with approximately 15% average weight loss over 68 weeks. Oral semaglutide (Rybelsus) is approved for type 2 diabetes at 7 mg and 14 mg daily, with investigational work at 25 mg and 50 mg daily showing stronger glycemic and weight outcomes in the PIONEER PLUS trial.

GI side effects are the most common issue, affecting approximately 82% of users to some degree in obesity trials versus 54% in placebo groups - though most are mild to moderate and occur during dose escalation. Only 3.9% of semaglutide users discontinued due to GI events in those trials, according to published safety data. A Harvard and CDC analysis found that GI problems accounted for nearly 70% of all semaglutide side effect reports.

Generation Two - Dual GIP/GLP-1 Agonism

Tirzepatide represents the second generation. By adding GIP receptor activity to GLP-1 receptor activity, it achieves stronger metabolic outcomes than GLP-1-only compounds in head-to-head comparisons. Clinical trials for tirzepatide have shown weight loss outcomes in the 20-22% range at higher doses, outperforming semaglutide in direct comparison studies.

The mechanism behind tirzepatide's superior performance relative to pure GLP-1 agonists is still being fully characterized, but the dual receptor activity - particularly the prominent GIP receptor contribution to insulin secretion in human tissue - appears to drive stronger metabolic effects than either receptor alone.

Tirzepatide also has a unique pharmacological property: it is described as an "imbalanced" agonist with higher affinity and potency at the GIP receptor than at the GLP-1 receptor, and it exhibits biased agonism at the GLP-1 receptor toward cAMP signaling. These properties together may contribute to its clinical performance profile.

Generation Three - Triple GLP-1/GIP/Glucagon Agonism

Retatrutide, the compound the community calls "GLP-3," adds glucagon receptor activity to the dual agonism of tirzepatide. This is where the progression the community's numbering captures becomes scientifically real: each number does correspond to a more mechanistically complex compound.

Retatrutide is not yet FDA-approved. It is in Phase 3 clinical trials. Phase 2 data showed weight loss outcomes that exceeded both semaglutide and tirzepatide, with some trial cohorts showing greater than 24% average weight reduction over approximately 48 weeks. The glucagon receptor activity is theorized to drive this by increasing energy expenditure beyond what appetite suppression alone produces.

The triple agonist category also includes other compounds in development, but retatrutide is the one the research community has informally designated as "GLP-3" and the most prominently researched in this class.

How to Identify What You're Actually Looking At

If you are navigating supplier sites or community discussions and trying to figure out what a compound actually is behind its label, here is a practical approach.

Cross-Reference the Suffix Codes

The suffix letters that suppliers append to GLP labels are usually abbreviated versions of the actual compound name:

• -S, -SG, -SEMA → sema-glutide
• -T, -TIRZ, -TZ → tirze-patide
• -R, -RT, -RET → retatrutide

When you see a compound labeled with any GLP prefix followed by these suffixes, you have a reasonably reliable indicator of which compound is inside. Some suppliers use only the number (GLP-1, GLP-2, GLP-3) without a suffix, which means you are relying on the supplier's labeling convention alone - which is less informative.

Check the Mechanism Description

A legitimate supplier listing a compound in this class should describe the mechanism in a way that is consistent with the compound they are selling. For semaglutide, expect GLP-1 receptor agonist language. For tirzepatide, expect dual GIP/GLP-1 agonist language. For retatrutide, expect triple agonist or GLP-1/GIP/glucagon receptor agonist language.

If a product is labeled "GLP-2" and the mechanism description says "GLP-1 receptor agonist only" with no mention of GIP receptor activity, there is a mismatch worth investigating before purchasing.

Understand That the Community Shorthand Does Not Define Efficacy

The informal GLP-1/2/3 numbering is not a hierarchy of effectiveness in any simple sense. The compounds differ mechanistically, and their relative performance depends on the goal, the individual, and the dose. Retatrutide being "GLP-3" does not mean it is simply a better version of semaglutide that everyone should pursue. It means it is a mechanistically more complex compound with a different receptor profile that is still under clinical development.

Semaglutide has a deep clinical evidence base. Tirzepatide has strong Phase 3 data. Retatrutide has compelling Phase 2 data but has not yet completed the full approval process. Choosing among them - in any research context - involves understanding those distinctions, not just following the numbering.

The Supplement Market's Version of "GLP" Naming - A Different Problem

It is worth briefly addressing a parallel naming confusion that exists outside the research peptide space: supplements marketed as "GLP-1 boosters," "GLP-2 supplements," or in some cases "GLP-3 activators."

These products have nothing to do with the compounds described above. They are dietary supplements - typically containing ingredients like berberine, certain fiber types, or other compounds that may modestly influence incretin system activity through indirect pathways. Some of these ingredients have genuine research support for metabolic effects; none of them replicate the pharmacology of GLP-1 receptor agonist drugs.

When supplement companies use "GLP-3" in marketing, they are not describing a real receptor target. They are borrowing the trending GLP terminology to position their product adjacent to the buzz around GLP-1 drugs. A supplement labeled "GLP-3" does not contain retatrutide. It does not activate a GLP-3 receptor. It is a supplement with whatever ingredients are in the formula.

This is a different layer of naming confusion from the research peptide community's informal shorthand, but the result for consumers is similar: seeing a number after "GLP" and assuming it means something specific about the pharmacology, when the label is doing something else entirely.

The Regulatory Picture for Each Compound

Understanding what each compound's regulatory status is helps frame what "buying" them actually means in different contexts.

Semaglutide (the community's GLP-1) is FDA-approved in multiple formulations: Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as an oral option for type 2 diabetes. Branded product requires a prescription. Compounded semaglutide was available through compounding pharmacies during and following an FDA shortage period, though the FDA has moved to restrict compounding as the shortage status has been resolved. The regulatory landscape for compounded semaglutide is actively evolving.

Tirzepatide (the community's GLP-2) is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Also prescription-only. Compounded versions have followed a similar trajectory to semaglutide.

Retatrutide (the community's GLP-3) is not FDA-approved for any indication. It is in Phase 3 clinical trials. In research contexts, it is available through suppliers operating in the research compound space, which is the primary context where the GLP3-RT labeling appears.

Products claiming GLP-3 drug effects without FDA approval - particularly supplements - cannot legally do so under current regulations. If a supplement is claiming to treat diabetes or obesity through a "GLP-3 mechanism," it is making a drug claim without a drug approval, which creates regulatory exposure under FTC and FDA guidelines.

FAQs

If GLP-1, GLP-2, and GLP-3 are just nicknames, why do suppliers use them?

Suppliers use the informal numbering because it has become standard community language, and buyers often search for these terms rather than the pharmaceutical names. The labels also provide some separation from regulated drug names like semaglutide and tirzepatide. It is a naming convention that emerged from community use and got adopted by suppliers as a practical matter, not because it reflects pharmacological classification.

Is retatrutide actually more powerful than semaglutide and tirzepatide?

Phase 2 clinical trial data for retatrutide showed weight loss outcomes that exceeded published semaglutide and tirzepatide results in some comparisons, with some cohorts reaching greater than 24% average weight reduction. However, retatrutide has not completed Phase 3 trials or received FDA approval, so the full safety and efficacy picture is not yet established. More mechanistic complexity does not automatically mean better outcomes for every individual or every goal.

What does "dual agonist" actually mean in plain language?

A dual agonist activates two receptor systems simultaneously. Tirzepatide activates the GLP-1 receptor (which drives appetite reduction, glucose-dependent insulin release, and gastric slowing) and the GIP receptor (which enhances insulin secretion and lipid metabolism). The two receptor systems together produce stronger metabolic effects than either system alone, which is why tirzepatide's clinical trial results have generally exceeded those of pure GLP-1 agonists.

Is there actually a GLP-2 receptor agonist drug I should know about?

Yes - teduglutide (brand name Gattex) is an FDA-approved GLP-2 receptor agonist. But it has nothing to do with weight loss or diabetes. It is approved exclusively for Short Bowel Syndrome, a condition where the intestine cannot absorb nutrients properly. GLP-2 promotes intestinal repair and growth. When the research community uses "GLP-2" to mean tirzepatide, they are not referring to this hormone or this drug class at all.

How do I tell if a supplier is selling real retatrutide vs. something mislabeled?

The suffix codes are a starting point: GLP3-R, GLP3-RT, and GLP3-RET are the most common labels for retatrutide in the research community. A credible supplier listing should describe the mechanism as a triple GLP-1/GIP/glucagon receptor agonist, which is the actual pharmacology. Certificate of analysis documentation from a third-party testing lab is the strongest evidence that what is in the vial matches the label. If a supplier cannot provide COA documentation, that is a sourcing quality concern regardless of what the compound is called.

Why do GLP-1 drugs cause nausea?

GLP-1 receptors exist in the gastrointestinal tract, and activating them slows gastric emptying - the rate at which food moves from the stomach into the small intestine. When gastric emptying slows significantly, nausea, bloating, and digestive discomfort can follow, particularly during dose escalation when the body is adjusting to the compound. Clinical trial data found approximately 82% of users experience some GI effects, though most are mild to moderate and resolve as dose escalation stabilizes.

Are any of these compounds on WADA's prohibited list for athletes?

GLP-1 receptor agonists are not currently on WADA's prohibited list. However, questions exist about their potential use for body composition in athletic contexts, and the regulatory picture may evolve as these compounds become more prevalent. There is no established WADA position on "GLP-3" as a category, partly because it is not a recognized pharmacological classification.

The GLP naming story does not have a tidy ending - the community shorthand is already entrenched, and suppliers are not going to stop using it. But knowing the decoder key and understanding the actual science behind each compound puts you in a much better position to evaluate what you are looking at, whether you are reading a supplier listing, a community discussion, or an article about the next-generation drug in this class.

What matters practically: semaglutide, tirzepatide, and retatrutide are three distinct compounds with increasing mechanistic complexity. The GLP-1/2/3 labels are community shorthand for those three compounds - useful once you know the code, misleading if you take them at face value as pharmacological descriptions. The real science is that all three are built on the GLP-1 receptor foundation, and each subsequent compound adds receptor systems on top of it. That progression is real. The numbering system that describes it just borrowed language from a completely different area of endocrinology to do so.